Neurogenic Orthostatic Hypotension
Chelsea Therapeutics announces results of European Phase IIb trial of Droxidopa
Published in Blood Weekly, February 15th, 2007
The primary objective of the trial was to determine the optimal dose of Droxidopa in the treatment of orthostatic hypotension in patients with multiple system atrophy (MSA) or Parkinson disease (PD). The double-blind, randomized, placebo-controlled, parallel group, Phase IIb trial, led by Christopher Mathias, DPhil, DSc, FRCP, professor of neurovascular medicine, Imperial College School of Medicine at St. Mary's Hospital, London, was conducted at 30...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-02-15)
More Articles from Blood Weekly
- Alcoholism Epidemiology
Research on alcoholism epidemiology published by scientists at Ohio State University, Division of Pulmonary - Blood Safety
New blood safety research reported from Rush University - Blood Substitutes
New blood substitutes study results reported from University of Michigan, Department of Surgery - Endotoxemia Genetics
Studies from University of Medicine & Dentistry of New Jersey provide new data on endotoxemia genetics - Epidemiology
Researchers from Medical School describe findings in epidemiology - Gestational Diabetes Risk Factors
New gestational diabetes risk factors research from University Hospital, Department of Pediatrics outlined - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
